Compare AHL & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AHL | MLYS |
|---|---|---|
| Founded | 2002 | 2019 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.1B |
| IPO Year | 2025 | 2023 |
| Metric | AHL | MLYS |
|---|---|---|
| Price | $37.02 | $38.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $39.44 | ★ $46.40 |
| AVG Volume (30 Days) | 241.6K | ★ 1.9M |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.46 | N/A |
| EPS | ★ 6.60 | N/A |
| Revenue | ★ $3,191,700,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.24 | N/A |
| P/E Ratio | $5.61 | ★ N/A |
| Revenue Growth | ★ 5.65 | N/A |
| 52 Week Low | $27.05 | $8.24 |
| 52 Week High | $37.19 | $47.65 |
| Indicator | AHL | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 42.94 |
| Support Level | N/A | $41.50 |
| Resistance Level | N/A | $44.13 |
| Average True Range (ATR) | 0.00 | 2.37 |
| MACD | 0.00 | -0.63 |
| Stochastic Oscillator | 0.00 | 15.49 |
Aspen Insurance Holdings Ltd is a Bermudian insurance and reinsurance company. Its principal business is marketing and underwriting specialty insurance and reinsurance regularly. It comprises underwriting operations, which include risk-bearing insurance and reinsurance operations; Investing activities, which support underwriting operations; and ACM operations, which earn underwriting, management, and performance fees. It has two segments: Aspen Insurance and Aspen Reinsurance. Aspen Insurance consists of property and casualty insurance, marine, aviation, and energy insurance, and financial and professional lines insurance. Aspen Reinsurance comprises property catastrophe reinsurance, other property reinsurance, casualty reinsurance, and specialty reinsurance.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.